APOE ε4 specific imbalance of arachidonic acid and docosahexaenoic acid in serum phospholipids identifies individuals with preclinical Mild Cognitive Impairment/Alzheimer's Disease

Laila Abdullah[1], James E. Evans[1], Tanja Emmerich[1], Gogce Crynen[1], Ben Shackleton[1], Andrew P. Keegan[1], Cheryl Luis[1], Leon Tai[2], Mary J. LaDu[2], Michael Mullan[1], Fiona Crawford[1], Corbin Bachmeier[1]

[1] Roskamp Institute, Sarasota, FL 34234, USA
[2] University of Illinois at Chicago, Chicago, IL 60607, USA

Correspondence to: Laila Abdullah; email: labdullah@rfdn.org

ABSTRACT

This study was designed to explore the influence of apolipoprotein E (APOE) on blood phospholipids (PL) in predicting preclinical Alzheimer's disease (AD). Lipidomic analyses were also performed on blood from an AD mouse model expressing human APOE isoforms (EFAD) and five AD mutations and from 195 cognitively normal participants, 23 of who converted to mild cognitive impairment (MCI)/AD within 3 years. APOE ε4-carriers converting to MCI/AD had high arachidonic acid (AA)/docosahexaenoic acid (DHA) ratios in PL compared to cognitively normal ε4 and non-ε4 carriers. Arachidonic acid and DHA containing PL species, ε4-status and Aβ42/Aβ40 ratios provided 91% accuracy in detecting MCI/AD. Fish oil/omega-3 fatty acid consumption was associated with lower AA/DHA ratios even among ε4 carriers. High plasma AA/DHA ratios were observed in E4FAD compared to EFAD mice with other isoforms. In particular, alterations in plasma AA and DHA containing PL species were also observed in the brains of E4FAD mice compared to E3FAD mice. Despite the small sample size and a short follow-up, these results suggest that blood PL could potentially serve as biomarkers of preclinical MCI/AD.

INTRODUCTION

The apolipoprotein E (APOE) ε4 allele is a major genetic risk factor for late-onset Alzheimer's disease (AD) which affects nearly 5 million individuals over the age of 65. Possession of an ε4 allele increases the risk of developing AD by 2-3 fold and occurs in nearly 60% of AD cases [1]. Compared to non-ε4 individuals, ε4 carriers exhibit brain amyloid pathology as early as age 40 and experience faster cognitive decline [2]. While the effects of the ε4 allele on brain AD pathology are known, it is unclear how the systemic effects of the ε4 allele contribute to the risk of developing AD. The apoE protein plays a key role in the transport and metabolism of lipids [3]. Therefore, investigation into the association between the APOE genotypes and blood lipids will be instrumental in determining their contribution to AD pathogenesis and their potential as biomarkers of preclinical AD, which are desperately needed to assist with early intervention efforts in AD.

Polyunsaturated fatty acids (PUFA) are required for maintaining the structure, function and vascular integrity of the brain [4, 5]. It has been proposed that the diminished capacity of apoE4 to transport PUFA contributes to the pathogenesis of AD [6]. The brain can synthesize non-essential fatty acids, but essential PUFA (e.g., arachidonic acid [AA] and docosahexaenoic acid [DHA]) are largely acquired from the peripheral circulation [7]. Arachidonic acid metabolism produces pro-inflammatory lipid metabolites, such as prostaglandins and leukotrienes, whereas metabolism of DHA generates anti-inflammatory mediators, such as resolvins [8, 9]. Hence, an increase in AA to DHA

ratios could promote inflammation, further contributing to AD pathogenesis [9].

In blood, apoE transports lipids to various organs, including the brain [10]. Animal studies have shown that mice with human APOE4 display impaired transport of DHA to the brain compared to mice with human APOE2 [6]. Only a small percentage of PUFA exist as free fatty acids in blood and the unesterified forms of certain PUFA (i.e. DHA) can enter the brain [11]. Majority of PUFA are esterified to TG and PL that are complexed with apoE containing lipoproteins [12, 13]. Once lipoproteins reach the blood-brain-barrier (BBB), esterified lipids are processed by lipases present in the brain endothelial cells, resulting in the release of PUFA and their subsequent transport into the brain by simple diffusion or by specialized transporters [12, 14-16].

Major blood PL classes include phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI) and lysophosphatidylcholine (LPC), where PC concentrations are highest relative to other PL classes [17]. Studies have shown that altered AA and DHA within blood PL are associated with AD diagnosis [18, 19]. However, it remains to be determined whether there are any ε4 genotype associated differences in AA and DHA containing PL between cognitively normal subjects and those with preclinical mild cognitive impairment (MCI)/AD. We hypothesized that an examination of AA and DHA content of PL classes alongside the APOE genotypes may predict preclinical MCI/AD. We performed lipidomic analyses of serum PL collected at baseline from a longitudinal cohort of cognitively normal individuals with a positive family history of late-onset AD or related dementia, of whom a subset converted to MCI or AD within 3 years. We also profiled plasma PL from mice with human APOE targeted replacement (APOE-TR) crossed with those harboring 5 familial AD mutations [20]. These studies suggest that the APOE genotypes together with AA and DHA within blood PL may be diagnostically important for detecting the preclinical stages of MCI/AD.

RESULTS

### An increase in AA to DHA ratios preceded the diagnosis of MCI/AD

We examined serum PL profiles in a longitudinal cohort of 195 individuals, of whom 15 converted to MCI and 8 converted to AD while 172 subjects remained cognitive normal over 3 years. The APOE ε4 allele was present in 31% of subjects who remained cognitive normal, 40% among those who converted to MCI and 50% in those who converted to AD. There were no baseline differences between MCI and AD subjects for age, education, gender and ethnicity ($p > 0.05$). Cognitive scores at the annual visit conducted at 24 months post-enrollment showed that MCI and AD subjects had similar scores for MMSE, immediate and delayed Rivermead Behavioral and delayed recall ($p > 0.05$). Values of Aβ42/Aβ40 ratios in MCI subjects (0.11 ± 0.01 SE) were intermediate between controls (0.16 ± 0.02 SE) and AD subjects (0.05 ± 0.01 SE. Comparisons of the differences for general demographics between individuals who remained cognitive normal and those who converted to MCI or AD with or without ε4 (Table 1). Although within the normal limits, the MMSE scores were significantly lower among ε4 carriers converting to MCI/AD compared to other groups (Table 1). None of the ε4 and non-ε4 carriers converting to MCI/AD reported using fish-oil or omega-3 fatty acid supplements. Among ε4 non-carriers

Table 1. Baseline demographics of the study cohort stratified by the APOE ε4 carrier status.

|	APOE ε4- control (n =119)	APOE ε4- MCI/AD (n = 13)	APOE ε4+ control (n = 53)	APOE ε4+ MCI/AD (n = 10)
	N (%)			
Female	60 (50)	6 (46)	29 (56)	2 (20)
Caucasian	117 (98)	13 (100)	51(96)	10 (100)
Fish oil/Omega-3	17 (14.3)	0 (0)	5 (9.4)	0 (0)
	Mean (± SE)			
Age	76.8 (0.38)	79.1 (1.0)	76.23 (0.50)	78.0 (1.3)
Education	14.4 (0.27)	15.3 (0.90)	15.1 (0.33)	13.9 (0.96)
MMSE	28.8 (0.13)	29.0 (0.25)	29.2 (0.15)	27.8 (0.44)*

Note: * indicates p < 0.05 based on ANOVA.

Figure 1. Ratios of AA to DHA and individual PL species stratified by diagnosis and the APOE ε4 carrier status. Mean ± SE (ε4-non carriers = 119 control and 13 MCI/AD; ε4 carrier = 53 controls and MCI/AD = 10). (**A**) There was an interaction between MCI/AD diagnosis and ε4 allele for PC (F = 10.81, p = 0.001), PE (F = 4.95, p = 0.027), PI (F = 9.13, p = 0.003) and LPC (F = 15.05, p < 0.001). Subjects with the ε4 allele who later converted to MCI/AD had higher ratios of AA to DHA within PC, LPC, PI and PE relative to ε4 controls and ε4 non-carriers. (**B**) Individual AA and DHA species which significantly contributed to the imbalance in AA to DHA ratios among ε4 carries with MCI/AD compared to other groups include ePC(36:4), ePC(40:4), PC(40:6), PE(38:4), PE(40:6), PE(40:8) and LPC(20:4). *p < 0.05 for post-hoc analyses.

who remained normal, 14.5% consumed fish oil or another form of an omega-3 fatty acid supplement. About 9% of control ε4 carriers consumed fish oil/omega-3 fatty acid supplements (p < 0.05, Table 1).

There were significant differences in the ratios of AA to DHA within PL between MCI/AD converters and those who remained normal and a confounding effect of the ε4 carrier status was observed (p < 0.05, Figure 1A). Supplementary Table 1 shows AA and DHA containing PL species, which contributed to high AA/DHA ratios among ε4 carrier AD patients compared to other groups. Within each PL class, there was a significant interaction between the ε4 carrier status and MCI/AD diagnosis, where *post-hoc* comparisons showed a significantly higher AA to DHA ratios among ε4 carriers who converted to MCI/AD compared to ε4 carriers who remained normal (p < 0.05, Figure 1A). Individual PL

species contributing to the imbalance in AA to DHA ratios are presented in Figure 1B. Among ε4 carriers, ratios of AA and DHA within each PL class were similar in MCI and AD subjects compared to controls (Supplemental Figure 1). The distribution of total and individual PL species associated with MCI/AD conversion is presented in the Supplementary Table 1. The degree of unsaturation was not differentially modulated with respect to the ε4 carrier status and MCI/AD diagnosis (Supplementary Figure 2). Figure 2 shows a pilot receiver operator curve (ROC) constructed using a regression model adjusted for confounding factors and consists of AA and DHA containing species, ε4 status and Aβ42/40 ratios. This model has highest accuracy for predicting preclinical AD with an AUC of 91% (95% CI (83-93%)), whereas PL species alone provide a lower accuracy with an AUC of 88% (95% CI (78% to 98%)), followed by


Figure 2. Arachidonic acid and DHA containing PL species along with ε4 carrier status and Aβ have high accuracy for predicting MCI/AD diagnosis. Pilot ROC analyses were performed using the Cox-regression model consisting of a panel of PL that contained AA and DHA which included PE(36:4), PE(38:6), ePE(40:6), PE(40:6), LPC(20:4), LPC(22:6), ePC(36;4), ePC(40:4), ePC(40:6), PC(36:4), PC(38:4), PC(38:5), PC(40:4), PC(40:6), and PC(40:7). An AUC of 91% towards the diagnosis of MCI/AD was observed for this PL panel, ε4 and Aβ42/Aβ40 ratios. PL species alone provide an AUC of 88%. The APOE and ε4 together provided an AUC of 71%.

Figure 3. Effect of fish oil/omega-3 supplement use on the AA and DHA containing species within blood PL classes.
Mean ± SE(17 ε4- controls and 5 ε4 controls) for subjects who reported yes for using fish oil/omega-3 supplement. (**A**) Relative to non-users, ratios of AA to DHA were decreased in several PL classes in both ε4- and ε4+ controls who reported using fish-oil/omega-3 supplements. (**B**) Individual AA species (ePC(36:4), ePC(38:4), PC(36:4), LPC(20:4)) were generally decreased whereas DHA containing species (PC(40:6), PC(40:7), ePE(40:6), PE(40:6), and PI(40:6) were increased in several PL classes in both ε4- and ε4+ controls who reported using fish-oil/omega-3 supplements. While LPC(22:6) was increased in supplement users with ε4- genotype, levels of this lipid did not change in ε4+ individuals. *p < 0.05 for post-hoc analyses.

Aβ42/Aβ40 ratios and ε4 which provide an AUC of 78% (95% CI [68-88%]) and ε4 alone provided the AUC of 71% (95% CI [59-83%]). A significant effect of fish oil/omega-3 fatty acid supplementation was observed on the ratios of AA to DHA. In most instances, the ratios were decreased in ε4 and non-ε4 subjects reporting yes to prior use of omega-3 or fish oil fatty acid supplementation compared to those reporting no to using these supplements (p < 0.05, Figure 3A). Figure 3B shows decreases in AA containing species and increases in DHA containing PL species in individuals reporting yes for omega-3/fish-oil supplement use, even among ε4 carriers. We also examined the effects of the study interventions on AA and DHA containing PL species and found that the naproxen intervention increased PC(36:4) and PC(38:5) and decreased ePE(40:6) compared to the placebo group (p < 0.05, Supplementary Figure 3).

An increase in AA to DHA ratios was observed in several PL classes in mice harboring APOE4 relative to other APOE isoforms

These studies explored possible validation of human findings in a preclinical model of AD that contained both APOE isoforms and AD relevant genetic errors (EFAD mice). To date, this is the only model available that allows an examination of APOE together with AD pathological markers, amyloid and tau. Plasma from mice expressing human APOE isoforms (APOE-TR and EFAD) were subjected to lipidomic analyses to determine their translational value when compared to the APOE genotype related PL differences observed in human samples. The ratios of AA to DHA containing species were elevated in mice with E4 relative to other isoforms for both mouse models at 6 months of age. Most notably, ratios were significantly higher for E4 compared to other isoforms in LPC and PC in APOE-TR mice and for PI in E4FAD compared to E2FAD and E3FAD mice (p < 0.05, Figure 4). Figure 4B shows the profiles of PL species that contributed to the observed imbalance of AA to DHA ratios in the APOE4 and E4FAD compared to other isoforms in both APOE-TR and EFAD mice. Supplementary Table 2 provides a summary of mean levels of total and individual PL species across APOE-TR and EFAD mice that were differentially modulated in the human studies above. Most species were significantly higher in E2 relative to other isoforms in both models. However, LPC(20:4) which contains AA (LPC-AA) was higher in E4 compared to other isoforms in both mouse models, whereas LPC(22:6) that contains DHA (LPC-DHA) was higher only in E4FAD when compared to other EFAD mice. The degree of unsaturation of PL classes was differentially modulated in LPC with plasma polyunsaturated fatty acids (PUFA) were high only

among E3FAD compared to E2FAD and E4FAD mice and monounsaturated fatty acid (MUFA) containing lipids were unaffected in EFAD mice (p < 0.05, Supplementary Figure 4). For the remainder of the PL classes, there was no differential modulation with respect to the degree of unsaturation since APOE2 and E2FAD were elevated compared to other genotypes, respectively (see Supplementary Figure 4). Supplementary Figure 5 shows a longitudinal profile of AA and DHA containing species, which contributed to AA/DHA ratio changes observed in E4FAD mice compared to E3FAD. Supplementary Figure 6 shows a reduction of certain AA and DHA containing PL species in the brains of E4FAD mice compared to E3FAD. However, LPC-AA and LPC-DHA were increased in plasma of E4FAD compared to E3FAD but decreased in the brains of E4FAD relative to E3FAD mice (Supplementary Figures 5 and 6).

DISCUSSION

AA and DHA are critical for maintaining brain health and regulating inflammation [21, 22]. The adult brain relies heavily on the importation of AA and DHA from the periphery since their endogenous synthesis within the brain is low [23]. Until recently, it was thought that only unesterified DHA was able cross the BBB [11]. However, recent studies have demonstrated that esterified DHA can also cross the BBB and enter the brain via specialized lipid transporters [16]. Therefore, dysregulation of peripheral DHA homeostasis could result in decreased brain penetration, potentially contributing to AD pathogenesis [24]. Given the ε4 allele is the most potent genetic risk factor for AD and apoE facilitates lipid transport, we investigated the relationship between ε4 and blood PL on the risk of developing AD.

Our pilot ROC analyses show that when combined in a panel, AA and DHA containing species, Aβ42/Aβ40 ratios and ε4 genotype have an excellent accuracy in predicting MCI/AD. In our prior report, we showed that within 3 years, Aβ42/Aβ40 ratios predict conversion to MCI/AD with low accuracy unless combined with neuropsychological tests [25, 26]. Administration of neuropsychological tests requires considerable expertise, which is not routinely available in the community clinics. Thus, availability of a blood biomarker panel, such as the one proposed here, is appealing for the community settings. While generalization of our findings to a broader population is limited since our cohort was enriched for the presence of first-degree relatives with AD [25], such a strategy is useful for identifying subjects who are at a higher risk of developing AD and who may benefit the most from early interventions. As this study evaluated a short time

Figure 4. Ratios of AA to DHA and individual PL species stratified by APOE4-TR and E4FAD mice. Mean ± SE (n = 6 per genotype). (**A**) There was a main effect of APOE genotypes on LPC (F = 10.53, p < 0.001) and PC (F = 33.73, p < 0.001). Relative to APOE2 and APOE3, ratio of AA to DHA containing species within PC and LPC were higher in APOE4 mice. There was also a main effect of the APOE genotypes in PE (F = 89.95, p < 0.001), ratios of AA to DHA were lower in APOE2 and APOE4 relative to APOE3 and ratios of AA to DHA were lowest in E2 FAD followed by E4FAD relative to E3FAD mice. There was also a main effect of the APOE genotypes for PI (F = 99.71, p < 0.001), where ratios were higher in E4 relative to E2 and E3FAD. (**B**) There were significant differences in various AA and DHA containing PL between the APOE genotypes for the APOE-TR and EFAD mice. While PL species, such as ePC(36:4), PC(38:4), ePE(38:4) and PI(36:4) were decreased in E4 relative to the other isoforms in APOE-TR and EFAD mice. LPC(20:4) and LPC(22:6) were increased in E4 mice relative to the other isoforms in APOE-TR and EFAD mice. *p < 0.05 for the post-hoc analyses.

period of about 3 years in a small cohort of 195 subjects, one can only infer a possible association of these PL species with an imminent risk of conversion to MCI/AD, which remains a limitation of this study. Since AD pathogenesis begins decades before the onset of clinical presentation [27], an evaluation of PL over a longer time period will determine their long-term predictive value in detecting AD.

We observed an increase in AA to DHA ratios within PC, LPC, PE and PI in ε4 carriers who converted to MCI/AD compared to cognitively normal ε4 subjects and non-ε4 carrier. The Framingham Heart Study reported that high blood DHA within PC was associated with reduced incidence of AD. However, this study did not comment on the AA content or the role of APOE genotypes [28]. Mapstone and colleagues reported that PC(38:6) and PC(40:6) (species containing DHA) were reduced in MCI/AD converters but they did not find any APOE genotype-dependent effects [29]. In another case-control study, PC(40:4), an AA containing species, was associated with a diagnosis of AD [30]. Findings reported by the AddNeuroMed consortium from a case-control study showed that these PC species together with the APOE genotype status can improve the accuracy for diagnosing AD [31]. Serum PE species containing AA and DHA were decreased in the pathologically confirmed AD cases compared to controls [32]. Mapstone et al., showed decreases in another form of PI in MCI/AD compared to controls [29]. To date, there have been no reports of an imbalance in AA to DHA within LPC in relation to APOE and MCI/AD diagnosis.

At 6 months of age, we found that APOE2 and E2FAD had much higher levels of PL compared to other genotypes in respective mouse models. The observed elevation would be consistent with the well-known role of APOE2 homozygous genotypes as a risk factor of type III hyperlipidemia [33]. At 6 months of age, an imbalance in AA and DHA was also observed in several PL classes in E4 mice compared to other isoforms in APOE-TR and EFAD mice. We also examined blood from EFAD mice at a range of ages covering 2.5 months to 18 months of age. At 6 months of age, extensive brain inflammation and amyloid pathology is observed in E4FAD mice relative to mice expressing other isoforms [34, 35]. This longitudinal profiling of E3FAD and E4FAD mice showed that several AA and DHA containing species were altered as early as 2.5 months of age, suggesting an association of these PL species with preclinical AD in this mouse model. An examination of E3FAD and E4FAD mice brain homogenates showed that several AA and DHA containing species that were elevated in blood (i.e. LPC(20:4), LPC(22:6), PC(40:6), and PC(38:4) of

E4FAD mice compared to E3FAD mice were decreased in the brains of E4FAD mice compared to E3FAD mice. These studies suggest possible reduction in the transport of AA and DHA containing species by the apoE4 isoform. It is possible that lipid carrying capacity of APOE might be due to differences in apoE protein levels. For instance, previous studies have reported that levels of apoE protein are decreased in APOE4 compared to APOE3 mice (for both APOE-TR and EFAD mice) and in individuals who are carriers of the APOE ε4 allele compared to non-carriers [20, 36, 37]. In particular, studies have shown that plasma apoE levels are much lower among ε4 homozygous MCI subjects who convert to AD [38]. These studies support further examination of systemic AA and DHA imbalance in relation to the APOE genotypes and their contribution to AD pathology. As a number of advances have been made in application of lipidomics and metabolomics technologies [39, 40] and since bioactive lipid metabolites of AA and DHA have profound effects on modulating neuroinflammation, the use of these sophisticated technologies [41] to examine AA and DHA metabolites will be extremely valuable in understanding the role of AA and DHA containing PL in AD pathogenesis.

We were unable to examine the influence of statins and anti-hypertensive medications due to their confounding effects on MCI/AD [25], which required their incorporation as covariates in our analyses. We examined the effects of the study interventions on AA and DHA containing PL and found that only the naproxen intervention resulted in an increase in AA containing PC species and a decrease in an DHA containing PE species. This would be consistent with the inhibition of the cyclooxygenase pathways following the treatment with naproxen. However, owing to the fact that the study interventions did not modify the trajectory of AD onset following these treatments, it remains to be determined if there is any value of modulating AA containing PL species in preventing MCI/AD. However, possible confounding effects of the relationship between PL modulation by naproxen and AD prevention by other lipid modifying approaches cannot be excluded and require a larger sample size to examine this. We did however examine the effects of fish oil/omega-3 fatty acid supplementation in controls as none of the MCI/AD patients reported using these supplements. Fish oil or omega-3 fatty acid supplementation is a well-known modifier of DHA and has been put forth as a strategy to modulate AD progression [4]. Several randomized clinical trials have shown that DHA supplementation in elderly subjects improved verbal recognition memory and the immediate and delayed recall to the degree where it matched to the test norms of individuals 7 years younger [5]. This

suggests that if DHA intervention was administered early, transition to pathologic aging could be reverted to normal aging. A prospective cohort study of 3000 elderly subjects in the Chicago Health and Aging study identified that unsaturated fat was negatively associated with the risk of developing AD [42]. Although these prospective studies show that the consumption of fish or fish-oil/omega-3 fatty acid supplements is protective against AD [4], they have not been consistently replicated in randomized clinical trials [43]. However, these studies did not account for APOE genotypes or baseline fish consumption or fish oil/omega-3 supplementation in their trial design. In our current study, an increase in AA containing and a decrease in DHA containing species corresponded with a decrease of AA to DHA ratios among subjects using these supplements compared to non-users for both ε4 carriers and non-carriers. These findings suggest that APOE genotype and fish oil/omega-3 fatty acid supplementation influence blood DHA levels and are consistent with a recent report showing that long-term DHA supplementation could affect AA and DHA levels even in APOE4 mice [44]. A recent animal study has shown that increasing brain DHA through diet can mitigate some aspects of inflammatory response to Aβ exposure [45]. Collectively, these studies suggest further exploration of the use of omega-3 fatty acid supplements strategy to intervene against the risk of developing AD among ε4 carriers.

Another factor driving the changes observed in peripheral DHA could be altered tissue distribution throughout the body, particularly in the brain. Recent rodent studies have shown that in healthy brains, more DHA reaches the brain when consumed as PL compared to TG [46]. Previous work has shown that LPC-DHA is a preferred carrier of DHA to the brain [47]. A more recent study showed that the major facilitator superfamily domain-containing protein 2 (mfsd2a) localized within the BBB uses electrochemical potential of sodium to preferentially transport LPC-DHA across the BBB [16]. In the absence of LPC-DHA, mfsd2a can transport LPC-AA across the BBB [16]. Another recent study showed that when peripherally administered, more LPC-DHA entered the brain the non-esterified DHA, partly because much more DHA is found esterified to LPC than non-esterified [11]. An increase in peripheral LPC-AA and LPC-DHA may be the result of impaired transport of this form of DHA into the brain. Recent studies have shown that DHA transport into the brain is impaired in mice with human E4 compared to E2 [6]. Our studies show that both LPC-AA and LPC-DHA were chronically elevated in E4FAD compared to E3FAD mice and LPC-AA was also elevated in ε4 carriers with preclinical MCI/AD compared to other groups. We propose that AA and DHA esterified to these PL should be examined to determine possible interactions with the APOE genotypes for their transit across the BBB. Future investigations into these aspects will likely clarify how the systemic effects of E4 and impaired lipid delivery to the brain contribute to AD pathogenesis.

In the present studies, we show an interaction between the ε4 status and high AA to DHA ratios with the risk of developing MCI/AD. We also demonstrate that combining the APOE genotypes, blood AA and DHA species and the Aβ42/Aβ40 ratio improves the accuracy for detecting preclinical MCI/AD. As such, this biomarker panel could be valuable for diagnosing preclinical MCI/AD. Such strategies for diagnosing AD at the pre-symptomatic stages are critically needed to advance early intervention efforts for preventing AD. Further examination of the interaction between APOE and PL for their collectively contributions to AD etiology is necessary in a larger cohort and over a longer follow-up period to fully ascertain the value of PL profiling in detecting preclinical AD.

METHODS

Subject selection

As part of an IRB approved ancillary study, samples were collected and banked from a subset of participants (n = 195) recruited from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT), a randomized, placebo-controlled, multi-center primary prevention trial. Subjects were randomly assigned to one of three groups: celecoxib (200 mg b.i.d.), naproxen sodium (200 mg b.i.d.) or placebo with an allocation ratio of 1:1:1.5, respectively, which was maintained in this sub-cohort (43% on placebo, 28% on celecoxib and 29% on naproxen). There was no effect of the study intervention on the diagnosis of MCI or AD [48] so we used all three intervention arms for this study. Full details of the data collection, measurements, and study procedures are available elsewhere [49]. A separate consent was obtained from each subject who participated in this sub-study.

Study participants were selected based on the presence of a first-degree relative with AD-like dementia. Participant eligibility was determined using a study specific standard questionnaire, a physical exam and a brief neuropsychological battery [25]. Although the original study design did not intend to recruit subjects who were related to each other, an incidental recruitment of subjects who might be related to each other is possible. We expect that such enrichment would be randomly distributed between controls and cases since the study was a randomized controlled trial.

Blood draws were conducted at the semi-annual visits and the cognitive status was captured on an annual cognitive assessment. Data on medication use and supplement (i.e. fish oil) use was collected based on self-report. The cognitive measures completed at baseline and annual follow-up included the Modified Mini-Mental State Examination [50], the Hopkins Verbal Learning Test-Revised [51] and the Wechsler Adult Intelligence Scale-Revised (WAIS-R; [52]), see details elsewhere [26]. Collateral respondents completed the Dementia Severity Rating Scale [53].

Individuals scoring below the normal cut-off underwent a dementia work-up including the physical and neurological examinations, laboratory studies and neuroimaging as applicable [26]. A comprehensive neuropsychological assessment was administered as part of the dementia work-up. This battery of tests included the expanded Consortium to Establish a Registry for Alzheimer's Disease battery [54]; Logical Memory I and II of the Wechsler Memory Scale–Revised (Wechsler), and Benton Visual Retention Test (Benton), see additional details elsewhere [26]. A consensus team provided a diagnosis of AD in accordance with the NINCDS-ADRDA [55]. Amnestic MCI had impairment of at least one cognitive domain, including memory, executive function, attention, language, and visuospatial skill and had preserved independent living activities, consistent with the Petersen criteria [56]. Efforts were made to rule other causes for cognitive impairment such as vascular, traumatic and other medical causes of cognitive decline as per Albert and colleagues [57]. Amnestic MCI patients are in a transitional stage between normal aging and AD, with 85% of MCI subjects converting to AD within 7 years [58]. An imaging study showed that patterns of brain atrophy in amnestic MCI patients is typical of that observed in AD patients [59]. Therefore, owing to a small sample size of subjects who converted to either MCI or AD, we combined these diagnostic categories to facilitate adequate sampling for estimating disease progression.

Animals

Each mouse was housed in a controlled environment (12-hr light/dark cycle) and maintained on a standard diet. All animal experiments were approved by the Roskamp Institute Institutional Animal Care and Use Committee and conducted in accordance with the Office of Laboratory Animal Welfare and the Association for the Assessment Accreditation and Laboratory Animal Care guidelines. Transgenic mice expressing 5 familial AD mutations (5 x FAD) were crossed with APOE-TR mice (5 x FAD+/- human APOE+/+ (E2FAD, E3FAD, E4FAD)) as previously described [60]. Briefly, to

generate EFAD mice, 5 x familial AD mice were bred with homozygous APOE2, APOE3 and APOE4-TR mice (Taconic Laboratories). Male APOE-TR homozygous mice (background C57BL6) were bred with female 5 x FAD heterozygous (background C57B//B6x SJL). The resulting female with mouse-APOE/APOE-TR/FXFAD were then backcrossed with male APOE-TR mice to produce APOE-TR homozygous/5xFAD heterozygous mice. For this study, 6-month old male EFAD and 4-5 month old male APOE-TR mice were utilized (n = 6 per group). Biochemical analyses show that male FAD mice accumulate significant extracellular Aβ in the subiculum and the frontal cortex from 2-6 months, with E4FAD > E3FAD = E2FAD. At 6 months of age, compared to E3FAD, E4FAD mice exhibited neuroinflammation, which is characterized by a higher level of microgliosis and astrogliosis [34, 61]. A greater load of cerebral amyloid angiopathy and amyloid plaque in the cortex is evident in 7-month old female E4FAD relative to E2FAD and E3FAD male and female mice [62] and a greater cognitive impairment in the E4FAD mice than in E3FAD and E2FAD mice [63]. To determine PL changes with age in relation to APOE and AD pathology, we also examined plasma from 2.5 months and 18 months old (male/female) E3FAD and E4FAD mice (n = 5/6 mice per group for each age). Due to difficulties in breeding mice with the APOE2 genotypes, E2FAD mice were not available for these studies [64]. Cortical brain homogenates were prepared as previously described [20]. Briefly, frozen cortices from dissected brains were homogenized in 15 volumes (w/v) of TBS, then centrifuged (100,000 x g, 1hr at 4 °C), after which the pellet was washed in TBS, resuspended in again in 15 volumes of TBS buffer containing 1% TBSX and mixed gently by rotation at 4 °C for 30 min. Samples were centrifuged again (100,000 x g, 1hr at 4 °C) and TBSX soluble fraction was collected and frozen in -80°C for future studies [20]. Total protein content in the TBSX extractions was determined via colorimetric BCA assay per the manufacturer's instructions.

Sample collection, preparation and measurements

In human subjects, non-fasting blood draws were conducted by trained phlebotomists. Serum from blood of consenting subjects was processed using standard laboratory procedures [65]. To obtain mouse plasma, mice were exsanguinated via cardiac puncture using an 18-gauge wide-bore needle to prevent hemolysis of red blood cells (RBC) during blood collection. Blood samples were collected into a 1.5 ml Eppendorf tube containing EDTA. Samples were immediately centrifuged at 3000 x g for 5 min and plasma was snap frozen in liquid nitrogen.

Lipidomics

The Folch extraction of serum and plasma samples was performed as previously described [66-68] using the Folch method [69] following an addition of di-14:0 fatty acid (FA) containing PC and PE (Matreya, Pleasant Gap, PA), di-16:0 PI, and 14:0 LPC (Avanti, Albaster, AL) as internal standards. High-pressure liquid chromatography (HPLC) was achieved using a 1mm ID x 10 cm column containing Pinnacle II 3 μm silica particles (Restek, Bellefonte, PA, USA). A gradient was run from 10% solvent B (80% methanol, 10 mM formic acid, 5 mM ammonium hydroxide) in solvent A (chloroform-acetonitrile, 2:1) to 55% B in A for 12 min with a 5 min hold at the final conditions. The flow rate was 50 μl/min with the column temperature at 40° C. Mass spectrometry was performed with a Thermo LTQ linear ion trap mass spectrometer (Thermo-Fisher). Alternant positive and negative ion spectra were acquired from m/z 75 to 2,000 with in-source collision induced dissociation (SCID) and relative energies of 85% (positive ion) and 40% (negative ion). All spectra were obtained with a 200 ms maximum ion time and by summing 5 microscans. Mass spectra were summed over the chromatographic peak for each PL class, converted to listings with a threshold of 0.01% base ion intensity, exported to Microsoft Excel and then analyzed using LipidomeDB online to identify and quantify (with reference to the added internal standards) each PL molecular species [70]. Within each class, molecular species identified were totaled to generate total PC, PE and PI values. Each PL class was then analyzed and individual species containing saturated fatty acid (SFA), monounsaturated fatty acid (MUFA) or polyunsaturated fatty acid (PUFA) were grouped separately to generate a composite variable for each category. For PC, ratios were calculated using docosahexaenoic acid (DHA)-containing species, PC38:6 (16:0/22:6), PC40:6 (18:0/22:6) and PC40:7 (18:1/22:6), to arachidonic acid (AA)-containing species, ePC36:4 (16/20:4), ePC40:4 (20:0/20:4) PC36:4 (16:0/20:4), PC38:4 (18:0/20:4), and PC38:5 (18:1/20:4). For PE, a ratio of DHA-containing species, PE40:6 (18:0/22:6) and ether PE (ePE40:6, (18:0/22:6), to AA-containing species, PE36:4 (16:0/20:4) ePE36:4 (16:0/20:4), PE38:4 (18:0/20:4) and ePE38:4 (18:0/20:4), was calculated. For PI, a ratio of DHA-containing PI40:6 (18:0/22:6) to AA-containing PI36:4 (16:0/20:4) and PI38:4 (18:0/20:4) species was examined.

Statistical analyses

For human samples, baseline differences were compared across the study population using either the Student's t-test or the Chi-square statistics. Most PL classes were normally distributed but a few PE species were log transformed for normalization. Lipidomic data were analyzed using principal component analysis (PCA) followed by mixed linear model (MLM) as described previously [67] to examine the independent effects of the APOE genotypes and MCI/AD diagnosis and any potential interaction between them on PL profiles. Post-hoc correction for multiple hypothesis testing was performed using Benjamini–Hochberg procedure (B-H) on p-values obtained using the least significant differences. Cox regression modeling was used to test whether AA and DHA containing PL species, the ε4 allele and Aβ42/Aβ40 ratios alone or in combination can predict conversion to MCI/AD. For Cox regression, age, education, gender, creatinine and treatment with statins or anti-hypertensive medications were included as covariates to limit their confounding effects [25]. We performed pilot receiver operator curves (ROC) analyses to assess each model in predicting the diagnosis of MCI/AD. Mouse data were analyzed using MLM regression as detailed above. All statistical analyses were performed using SPSS version 23 (IBM, NY, US).

Abbreviations

AD: Alzheimer's disease; MCI: mild cognitive impairment; PL: phospholipid; PC: phosphatidylcholine; PE: phosphatidylethanolamine; PI: phosphatidylinositol; LPC: lyso-phosphatidylcholine; ROC: receiver operator curves.

AUTHOR CONTRIBUTIONS

All authors contributed to data collection/analysis, manuscript preparation and finalization of the manuscript. LA, JE, and CB also contributed to the conception and design of the study.

ACKNOWLEDGMENTS

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

FUNDING

REFERENCES

1. Crean S, Ward A, Mercaldi CJ, Collins JM, Cook MN, Baker NL, Arrighi HM. Apolipoprotein E ε4 prevalence in Alzheimer's disease patients varies across global populations: a systematic literature review and meta-analysis. Dement Geriatr Cogn Disord. 2011; 31:20–30. doi: 10.1159/000321984

2. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, et al, and Amyloid Biomarker Study Group. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015; 313:1924–38. doi: 10.1001/jama.2015.4668

3. Mahley RW. Central nervous system lipoproteins: ApoE and regulation of cholesterol metabolism. Arterioscler Thromb Vasc Biol. 2016; 36:1305–15. doi: 10.1161/ATVBAHA.116.307023

4. Bazinet RP, Layé S. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci. 2014; 15:771–85. doi: 10.1038/nrn3820

5. Salem N Jr, Vandal M, Calon F. The benefit of docosahexaenoic acid for the adult brain in aging and dementia. Prostaglandins Leukot Essent Fatty Acids. 2015; 92:15–22. doi: 10.1016/j.plefa.2014.10.003

6. Vandal M, Alata W, Tremblay C, Rioux-Perreault C, Salem N Jr, Calon F, Plourde M. Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2. J Neurochem. 2014; 129:516–26. doi: 10.1111/jnc.12640

7. Guest J, Garg M, Bilgin A, Grant R. Relationship between central and peripheral fatty acids in humans. Lipids Health Dis. 2013; 12:79. doi: 10.1186/1476-511X-12-79

8. Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol. 2008; 3:279–312. doi: 0.1146/annurev.pathmechdis.3.121806.151409

9. Sanchez-Mejia RO, Mucke L. Phospholipase A2 and arachidonic acid in Alzheimer's disease. Biochim Biophys Acta. 2010; 1801:784-90.

10. Barberger-Gateau P, Samieri C, Féart C, Plourde M. Dietary omega 3 polyunsaturated fatty acids and Alzheimer's disease: interaction with apolipoprotein E genotype. Curr Alzheimer Res. 2011; 8:479–91. doi: 10.2174/156720511796391926

11. Chen CT, Kitson AP, Hopperton KE, Domenichiello AF, Trépanier MO, Lin LE, Ermini L, Post M, Thies F, Bazinet RP. Plasma non-esterified docosahexaenoic acid is the major pool supplying the brain. Sci Rep. 2015; 5:15791. doi: 10.1038/srep15791

12. Spector AA. Plasma free fatty acid and lipoproteins as sources of polyunsaturated fatty acid for the brain. J Mol Neurosci. 2001; 16:159–65. doi: 10.1385/JMN:16:2-3:159

13. Quehenberger O, Armando AM, Brown AH, Milne SB, Myers DS, Merrill AH, Bandyopadhyay S, Jones KN, Kelly S, Shaner RL, Sullards CM, Wang E, Murphy RC, et al. Lipidomics reveals a remarkable diversity of lipids in human plasma. J Lipid Res. 2010; 51:3299–305. doi: 10.1194/jlr.M009449

14. Hamilton JA, Hillard CJ, Spector AA, Watkins PA. Brain uptake and utilization of fatty acids, lipids and lipoproteins: application to neurological disorders. J Mol Neurosci. 2007; 33:2–11. doi: 10.1007/s12031-007-0060-1

15. Polozova A, Salem N Jr. Role of liver and plasma lipoproteins in selective transport of n-3 fatty acids to tissues: a comparative study of 14C-DHA and 3H-oleic acid tracers. J Mol Neurosci. 2007; 33:56–66. doi: 10.1007/s12031-007-0039-y

16. Nguyen LN, Ma D, Shui G, Wong P, Cazenave-Gassiot A, Zhang X, Wenk MR, Goh EL, Silver DL. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature. 2014; 509:503–06. doi: 10.1038/nature13241

17. Dashti M, Kulik W, Hoek F, Veerman EC, Peppelenbosch MP, Rezaee F. A phospholipidomic analysis of all defined human plasma lipoproteins. Sci Rep. 2011; 1:139. doi: 10.1038/srep00139

18. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, Hall WJ, Fisher SG, Peterson DR, Haley JM, Nazar MD, Rich SA, Berlau DJ, et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med. 2014; 20:415–18. doi: 10.1038/nm.3466

19. Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH. Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids. 2000; 35:1305–12. doi: 10.1007/s11745-000-0646-3

20. Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, Kim J, Eimer WA, Estus S, Rebeck GW, Weeber EJ, Bu G, Yu C, Ladu MJ. APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem. 2012; 287:41774–86. doi: 10.1074/jbc.M112.407957

21. González-Domínguez R, García-Barrera T, Gómez-Ariza JL. Combination of metabolomic and phospholipid-profiling approaches for the study of Alzheimer's disease. J Proteomics. 2014; 104:37–47. doi: 10.1016/j.jprot.2014.01.014

22. Veszelka S, Tóth AE, Walter FR, Datki Z, Mózes E, Fülöp L, Bozsó Z, Hellinger E, Vastag M, Orsolits B, Környei Z, Penke B, Deli MA. Docosahexaenoic acid reduces amyloid-β induced toxicity in cells of the neurovascular unit. J Alzheimers Dis. 2013; 36:487–501.

23. Mitchell RW, Hatch GM. Fatty acid transport into the brain: of fatty acid fables and lipid tails. Prostaglandins Leukot Essent Fatty Acids. 2011; 85:293–302. doi: 10.1016/j.plefa.2011.04.007

24. Hennebelle M, Plourde M, Chouinard-Watkins R, Castellano CA, Barberger-Gateau P, Cunnane SC. Ageing and apoE change DHA homeostasis: relevance to age-related cognitive decline. Proc Nutr Soc. 2014; 73:80–86. doi: 10.1017/S0029665113003625

25. Abdullah L, Luis C, Paris D, Mouzon B, Ait-Ghezala G, Keegan AP, Wang D, Crawford F, Mullan M. Serum Abeta levels as predictors of conversion to mild cognitive impairment/Alzheimer disease in an ADAPT subcohort. Mol Med. 2009; 15:432–37.

26. Luis CA, Abdullah L, Ait-Ghezala G, Mouzon B, Keegan AP, Crawford F, Mullan M. Feasibility of predicting MCI/AD using neuropsychological tests and serum β-Amyloid. Int J Alzheimers Dis. 2011; 2011:786264. doi: 10.4061/2011/786264

27. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7:280–92. doi: 10.1016/j.jalz.2011.03.003

28. Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Tucker KL, Kyle DJ, Wilson PW, Wolf PA. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol. 2006; 63:1545–50. doi: 10.1001/archneur.63.11.1545

29. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, Hall WJ, Fisher SG, Peterson DR, Haley JM, Nazar MD, Rich SA, Berlau DJ, et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med. 2014; 20:415–18. doi: 10.1038/nm.3466

30. Proitsi P, Kim M, Whiley L, Simmons A, Sattlecker M, Velayudhan L, Lupton MK, Soininen H, Kloszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, et al. Association of blood lipids with Alzheimer's disease: A comprehensive lipidomics analysis. Alzheimers Dement. 2017; 13:140–51. doi: 10.1016/j.jalz.2016.08.003

31. Whiley L, Sen A, Heaton J, Proitsi P, García-Gómez D, Leung R, Smith N, Thambisetty M, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, et al, and AddNeuroMed Consortium. Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiol Aging. 2014; 35:271–78. doi: 10.1016/j.neurobiolaging.2013.08.001

32. Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahiahonu PW, Heath D, Yamazaki Y, Flax J, Krenitsky KF, Sparks DL, Lerner A, Friedland RP, et al. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia. J Lipid Res. 2007; 48:2485–98. doi: 10.1194/jlr.P700023-JLR200

33. Utermann G, Kindermann I, Kaffarnik H, Steinmetz A. Apolipoprotein E phenotypes and hyperlipidemia. Hum Genet. 1984; 65:232–36. doi: 10.1007/BF00286508

34. Rodriguez GA, Tai LM, LaDu MJ, Rebeck GW. Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition. J Neuroinflammation. 2014; 11:111. doi: 10.1186/1742-2094-11-111

35. Tai LM, Ghura S, Koster KP, Liakaite V, Maienschein-Cline M, Kanabar P, Collins N, Ben-Aissa M, Lei AZ, Bahroos N, Green SJ, Hendrickson B, Van Eldik LJ, LaDu MJ. APOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective. J Neurochem. 2015; 133:465–88. doi: 10.1111/jnc.13072

36. Sullivan PM, Han B, Liu F, Mace BE, Ervin JF, Wu S, Koger D, Paul S, Bales KR. Reduced levels of human apoE4 protein in an animal model of cognitive impairment. Neurobiol Aging. 2011; 32:791–801. doi: 10.1016/j.neurobiolaging.2009.05.011

37. Nielsen HM, Chen K, Lee W, Chen Y, Bauer RJ 3rd, Reiman E, Caselli R, Bu G. Peripheral apoE isoform levels in cognitively normal APOE ε3/ε4 individuals are associated with regional gray matter volume and cerebral glucose metabolism. Alzheimers Res Ther. 2017; 9:5. doi: 10.1186/s13195-016-0231-9

38. Scarabino D, Broggio E, Gambina G, Maida C, Gaudio MR, Corbo RM. Apolipoprotein E genotypes and plasma levels in mild cognitive impairment conversion to Alzheimer's disease: A follow-up study. Am J Med Genet B Neuropsychiatr Genet. 2016; 171:1131–38. doi: 10.1002/ajmg.b.32495

39. Han X. Lipidomics for studying metabolism. Nat Rev Endocrinol. 2016; 12:668–79. doi: 10.1038/nrendo.2016.98

40. Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis. 2009; 35:165–76. doi: 10.1016/j.nbd.2009.02.019

41. Li B, Mahan CM, Kang HK, Eisen SA, Engel CC. Longitudinal health study of US 1991 Gulf War veterans: changes in health status at 10-year follow-up. Am J Epidemiol. 2011; 174:761–68. doi: 10.1093/aje/kwr154

42. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, Aggarwal N, Schneider J. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol. 2003; 60:940–46. doi: 10.1001/archneur.60.7.940

43. Chew EY, Clemons TE, Agrón E, Launer LJ, Grodstein F, Bernstein PS, and Age-Related Eye Disease Study 2 (AREDS2) Research Group. Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial. JAMA. 2015; 314:791–801. doi: 10.1001/jama.2015.9677

44. Chouinard-Watkins R, Pinçon A, Coulombe JD, Spencer R, Massenavette L, Plourde M. A diet rich in docosahexaenoic acid restores liver arachidonic acid and docosahexaenoic acid concentrations in mice homozygous for the human Apolipoprotein E ε4 allele. J Nutr. 2016; 146:1315–21. doi: 10.3945/jn.116.230052

45. Hopperton KE, Trépanier MO, Giuliano V, Bazinet RP. Brain omega-3 polyunsaturated fatty acids modulate microglia cell number and morphology in response to intracerebroventricular amyloid-β 1-40 in mice. J Neuroinflammation. 2016; 13:257. doi: 10.1186/s12974-016-0721-5

46. Kitson AP, Metherel AH, Chen CT, Domenichiello AF, Trépanier MO, Berger A, Bazinet RP. Effect of dietary docosahexaenoic acid (DHA) in phospholipids or triglycerides on brain DHA uptake and accretion. J Nutr Biochem. 2016; 33:91–102. doi: 10.1016/j.jnutbio.2016.02.009

47. Picq M, Chen P, Perez M, Michaud M, Véricel E, Guichardant M, Lagarde M. DHA metabolism: targeting the brain and lipoxygenation. Mol Neurobiol. 2010; 42:48–51. doi: 10.1007/s12035-010-8131-7

48. ADAPT-FS Research Group. Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study. Alzheimers Dement. 2015; 11:216–25.e1. doi: 10.1016/j.jalz.2014.03.009

49. Meinert CL, McCaffrey LD, Breitner JC, and ADAPT Research Group. Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results. Alzheimers Dement. 2009; 5:93–104. doi: 10.1016/j.jalz.2008.09.004

50. Teng EL, Chui HC. The modified mini-mental state (3MS) examination. J Clin Psychiatry. 1987; 48:314–18.

51. Woods SP, Scott JC, Conover E, Marcotte TD, Heaton RK, Grant I, and HIV Neurobehavioral Research Center Group. Test-retest reliability of component process variables within the Hopkins Verbal Learning Test-Revised. Assessment. 2005; 12:96–100. doi: 10.1177/1073191104270342

52. Wechsler D. Wechsler Adult Intelligence Scale-Revised Manual (The Psychological Corporation, New York). 1981.

53. Clark CM, Ewbank DC. Performance of the dementia severity rating scale: a caregiver questionnaire for rating severity in Alzheimer disease. Alzheimer Dis Assoc Disord. 1996; 10:31–39.

54. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989; 39:1159–65. doi: 10.1212/WNL.39.9.1159

55. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34:939–44. doi: 10.1212/WNL.34.7.939

56. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999; 56:303–08. doi: 10.1001/archneur.56.3.303

57. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7:270–79.
doi: 10.1016/j.jalz.2011.03.008

58. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001; 56:1133–42. doi: 10.1212/WNL.56.9.1133

59. Whitwell JL, Petersen RC, Negash S, Weigand SD, Kantarci K, Ivnik RJ, Knopman DS, Boeve BF, Smith GE, Jack CR Jr. Patterns of atrophy differ among specific subtypes of mild cognitive impairment. Arch Neurol. 2007; 64:1130–38.
doi: 10.1001/archneur.64.8.1130

60. Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, Kim J, Eimer WA, Estus S, Rebeck GW, Weeber EJ, Bu G, Yu C, Ladu MJ. APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem. 2012; 287:41774–86. doi: 10.1074/jbc.M112.407957

61. Tai LM, Ghura S, Koster KP, Liakaite V, Maienschein-Cline M, Kanabar P, Collins N, Ben-Aissa M, Lei AZ, Bahroos N, Green SJ, Hendrickson B, Van Eldik LJ, LaDu MJ. APOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective. J Neurochem. 2015; 133:465–88.
doi: 10.1111/jnc.13072

62. Cacciottolo M, Christensen A, Moser A, Liu J, Pike CJ, Smith C, LaDu MJ, Sullivan PM, Morgan TE, Dolzhenko E, Charidimou A, Wahlund LO, Wiberg MK, et al, and Alzheimer's Disease Neuroimaging Initiative. The APOE4 allele shows opposite sex bias in microbleeds and Alzheimer's disease of humans and mice. Neurobiol Aging. 2016; 37:47–57.
doi: 10.1016/j.neurobiolaging.2015.10.010

63. Liu Y, Yu JT, Wang HF, Han PR, Tan CC, Wang C, Meng XF, Risacher SL, Saykin AJ, Tan L. APOE genotype and neuroimaging markers of Alzheimer's disease: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2015; 86:127–34.
doi: 10.1136/jnnp-2014-307719

64. Corbo RM, Scacchi R, Cresta M. Differential reproductive efficiency associated with common apolipoprotein e alleles in postreproductive-aged subjects. Fertil Steril. 2004; 81:104–07.
doi: 10.1016/j.fertnstert.2003.05.029

65. Abdullah L, Paris D, Luis C, Quadros A, Parrish J, Valdes L, Keegan AP, Mathura V, Crawford F, Mullan M. The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels. Neurosci Lett. 2007; 428:53–58.
doi: 10.1016/j.neulet.2007.09.058

66. Abdullah L, Evans JE, Bishop A, Reed JM, Crynen G, Phillips J, Pelot R, Mullan MA, Ferro A, Mullan CM, Mullan MJ, Ait-Ghezala G, Crawford FC. Lipidomic profiling of phosphocholine-containing brain lipids in mice with sensorimotor deficits and anxiety-like features after exposure to Gulf War agents. Neuromolecular Med. 2012; 14:349–61.
doi: 10.1007/s12017-012-8192-z

67. Abdullah L, Evans JE, Ferguson S, Mouzon B, Montague H, Reed J, Crynen G, Emmerich T, Crocker M, Pelot R, Mullan M, Crawford F. Lipidomic analyses identify injury-specific phospholipid changes 3 mo after traumatic brain injury. FASEB J. 2014; 28:5311–21. doi: 10.1096/fj.14-258228

68. Abdullah L, Evans JE, Joshi U, Crynen G, Reed J, Mouzon B, Baumann S, Montague H, Zakirova Z, Emmerich T, Bachmeier C, Klimas N, Sullivan K, et al. Translational potential of long-term decreases in mitochondrial lipids in a mouse model of Gulf War Illness. Toxicology. 2016; 372:22–33.
doi: 10.1016/j.tox.2016.10.012

69. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957; 226:497–509.

70. Zhou Z, Marepally SR, Nune DS, Pallakollu P, Ragan G, Roth MR, Wang L, Lushington GH, Visvanathan M, Welti R. LipidomeDB data calculation environment: online processing of direct-infusion mass spectral data for lipid profiles. Lipids. 2011; 46:879–84. doi: 10.1007/s11745-011-3575-8

SUPPLEMENTARY MATERIALS

Supplemental Figures

Supplemental Figure 1. Ratio of AA to DHA are similar in ε4 carriers with MCI and AD compared to ε4 controls. Mean ± SEM (ε4 carrier = 53 controls, MCI =6AD = 4). With PC, LPC, PE and PI, ratios of AA to DHA containing species were increased in both MCI subjects and AD patients.

Supplemental Figure 2. Differential modulation of the degree of unsaturation of PL classes stratified by diagnosis and the APOE ε4 carrier status. Mean ± SEM (ε4-non-carriers = 119 control and 13 MCI/AD; ε4 carrier = 53 controls and MCI/AD = 10). Figure shows that there were no differences in the degree of unsaturation of PC, PE and PI across different diagnostic categories, even if stratified by the APOE ε4 carrier status. For LPC, all SFA, MUFA and PUFA elevated in ε4 carriers with MCI/AD compared to control subjects. $*p < 0.05$ for post-hoc analyses.

Supplemental Figure 3. Effect of NSAID intervention on AA and DHA containing PL species. Mean ± SEM (n = 198). There was no effect of celecoxib on any of the AA and DHA containing PL species when compared to the placebo group. Intervention with naproxen elevated several AA containing species (PC(36:4) and PC(38:5) and decreased DHA containing PE (ePE(40:6)) compared to placebo. *p < 0.05 for the post-hoc analyses.

Supplemental Figure 4. Degree of unsaturation of PL classes stratified by the APOE genotypes in APOE-TR and EFAD mice. Mean ± SEM (n = 6 per genotype). For most PC, PE and PI classes, SFA, MUFA and PUFA were elevated in the E2 compared other isoforms in APOE-TR and EFAD mice. For LPC, E2 had elevated levels of SFA compared to other genotypes for both APOE-TR and EFAD mice. For MUFA within LPC, only APOE2 was higher than APOE3 and APOE4 isoforms. However, PUFA were elevated in E4FAD compared to E3FAD only. *p < 0.05 for post-hoc analyses.

Supplemental Figure 5. Longitudinal plasma profiles of AA and DHA containing PL species in E3FAD and E4FAD mice. Mean ± SEM (n = 5/6 per genotype for each age group). There were significant differences between E3FAD and E4FAD with age for the levels AA containing PL species: ePC(36:4) PC(38:4), ePE(38:4), PI(36:4) and LPC(20:4) and for DHA containing species: PC(40:6), PC(40:7) ePE(40:6), PE(40:6) and LPC(22:6). *denotes p < 0.05 for the post-hoc analyses.

Supplemental Figure 6. Brain profiles of AA and DHA containing PL species in E3FAD and E4FAD mice. Mean ± SEM (n = 3/4 per genotype). Relative to E3FAD, E4FAD mice had lower AA containing PL species (ePC(36:4) PC(38:4), ePE(38:4), PI(36:4) and LPC(20:4) and for DHA containing species (PC(40:6), PC(40:7) ePE(40:6), PE(40:6) and LPC(22:6). *p < 0.05.

Supplementary table 1A. Total PL levels in control and MCI/AD subjects stratified by the APOE ε4 allele.

	ε4- control	ε4- MCI/AD	ε4+ control	ε4+ MCI/AD
Phospholipids	μM ± SE			
Total PC	2246 (38.9)	2203 (99.2)	2248 (54.6)	2279 (74.1)
Total LPC	187 (3.3)	184 (11.6)	168 (4.4)	234 (13.4)*
Total PE	163 (7.9)	138 (23.8)	171 (16.4)	109 (12.8)
Total PI	233 (11.2)	225 (13.3)	206 (27.8)	265 (37.4)

Note: * indicates p < 0.05 for interactive or confounding effect of APOE and diagnosis.

Supplementary table 1B. Phospholipid species in control and MCI/AD stratified by the APOE ε4 allele.

	ε4- control	ε4- MCI/AD	ε4+ control	ε4+ MCI/AD
Phospholipids	μM ± SE			
ePC(32:2)	3.1 (0.07)	2.9 (0.20)	2.8 (0.11)	3.3 (0.23)*
ePC(34:0)	2.4 (0.10)	2.5 (0.27)	2.1 (0.13)	3.0 (0.27)*
ePC(34:1)	8.0 (0.26)	7.2 (0.59)	7.6 (0.28)	9.2 (0.44)*
ePC(34:2)	9.7 (0.26)	9.1 (0.80)	9.3 (0.36)	11.5 (0.74)*
ePC(36:2)	13.8 (0.35)	12.0 (0.95)	14.2 (0.52)	15.9 (1.11)*
ePC(36:3)	8.3 (0.22)	7.2 (0.66)	7.8 (0.33)	10.6 (0.68)*
ePC(36:4)	17.4 (0.44)	15.4 (1.29)	16.8 (0.67)	21.1 (1.00)*
ePC(38:2)	1.9 (0.04)	1.8 (0.07)	1.8 (0.05)	2.3 (0.12)*
ePC(38:6)	13.3(0.29)	11.4 (0.83)	12.6 (0.41)	13.7 (0.66)
ePC(40:4)	5.5 (0.10)	5.5 (0.27)	5.6 (0.17)	6.9 (0.51)*
PC(38:6)	105.1 (2.32)	101.8 (5.72)	103.1 (3.34)	80.0 (7.36)*
PC(40:4)	6.6 (0.13)	6.6 (0.40)	6.4 (0.20)	7.1 (0.37)
PC(40:6)	48.1 (1.03)	46.9 (3.09)	47.5 (1.62)	37.3 (3.58)*
PC(40:7)	15.8 (0.33)	14.2 (0.89)*	15.8 (0.60)	13.5 (1.25)*
PC(42:11)	3.6 (0.08)	3.1 (0.28)	3.6 (0.14)	4.7 (0.32)*
eLPC(16:0)	1.4 (0.03)	1.23 (0.06)	1.3 (0.03)	1.8 (0.09)*
eLPC(18:0)	1.7 (0.04)	1.5 (0.10)	1.5 (0.06)	2.1 (0.15)*
LPC(16:0)	75.9 (1.51)	73.0 (4.40)	68.7 (2.00)	92.4 (4.98)*
LPC(16:1)	1.6 (0.06)	1.6 (0.19)	1.4 (0.07)	2.0 (0.17)*
LPC(18:0)	39.8 (0.74)	36.3 (2.1)	36.1 (0.98)	48.8 (2.49)*
LPC(18:1)	22.7 (0.43)	24.3 (1.90)	20.1 (0.51)	29.9 (2.01)*
LPC(18:2)	27.3 (0.58)	28.9 (2.44)	24.2 (0.72)	36.3 (3.11)*
LPC(20:5)	4.2 (0.13)	4.8 (0.35)	3.9 (0.18)	5.6 (0.47)*
LPC(20:4)	9.1 (0.19)	9.3 (0.71)	8.0 (0.23)	11.7 (0.71)*
LPC(22:6)	1.8 (0.04)	1.7 (0.15)	1.6 (0.06)	1.7 (0.15)
ePE(36:5)	10.0 (0.51)	6.8 (1.10)*	9.9 (0.94)	6.4 (0.81)*
ePE(40:6)	4.2 (0.22)	3.2 (0.52)*	4.2 (0.39)	2.9 (0.36)*
PE(36:2)	11.7 (0.61)	13.3 (3.44)	12.7 (1.28)	8.0 (0.92)*
PE(36:4)	8.2 (0.44)	7.4 (1.28)	8.7 (1.05)	5.5 (0.64)*
PE(38:5)	8.0 (0.46)	7.4 (1.61)	8.9 (1.05)	5.1 (0.68)*
PE(38:6)	10.2 (0.62)	8.3 (1.51)*	12.0 (1.54)	4.2 (0.50)*
PE(40:6)	6.1 (0.38)	5.0 (1.07)*	7.4 (1.02)	2.4 (0.35)*
PI(36:0)	0.51 (0.03)	0.44 (0.05)	0.50 (0.05)	0.6 (0.07)*
PI(36:1)	9.3 (0.33)	9.7 (1.06)	9.1 (0.51)	12.0 (1.61)*
PI(36:2)	30.5 (1.05)	30.1 (3.15)	31.2 (1.81)	41.4 (5.88)*
PI(36:3)	9.0 (0.33)	8.5 (0.94)	9.1 (0.52)	11.3 (1.38)
PI(38:5)	13.3 (0.66)	10.4 (1.45)*	12.4 (0.71)	15.2 (1.99)

Note: These individual molecular species were part of the PCA significantly associated with MCI/AD diagnosis. *indicates p < 0.05 for interactive or confounding between APOE and diagnosis on PL levels. There was a main diagnosis effect for PC(40:7), ePE36:5, ePE40:7, PE38:6 and PE(40:6).

Supplementary table 2A. Total PL stratified by APOE genotypes in APOE-TR and EFAD mice.

	APOE2	APOE3	APOE4	E2FAD	E3FAD	E4FAD
	μM ± SE					
Total PC	3098 (57.4)	2403 (48.2)*	2016 (110.2)*	2515 (46.4)	2122 (63.2)	1976 (63.1)*
Total LPC	557 (12.9)	440 (4.0)*	392 (17.6)*	482 (10.6)	422 (11.0)	440 (9.3)*
Total PE	184 (7.6)	86 (2.3)*	79 (5.5)*	110 (3.5)	80 (1.8)*	72 (3.3)*
Total PI	384 (15.0)	195 (9.9)*	110 (13.6)*	202 (7.2)	104 (9.6)	96 (9.2)

Note: * indicates p < 0.05 for higher E2 vs. E3 and E4 for APOE-TR and for higher E2FAD vs. E3 and E4FAD. ** indicates p < 0.05 for higher E4 vs. E2 and E3 for APOE-TR and for E4FAD vs. E2FAD and E3FAD.

Supplementary Table 2B. Phospholipid species stratified by APOE genotypes in APOE-TR and EFAD mice.

	APOE2	APOE3	APOE4	E2FAD	E3FAD	E4FAD
	μM ± SE					
ePC(34:0)	1.2 (0.12)*	0.4 (0.07)	0.7 (0.08)	1.1 (0.08)*	0.34 (0.04)	0.5 (0.06)
ePC(34:1)	7.7 (0.22)*	4.7 (0.10)	4.0 (0.19)	5.7 (0.24)*	4.0 (0.09)	4.5 (0.17)
ePC(34:2)	8.1 (0.19)*	5.3 (0.23)	5.1 (0.38)	9.1 (0.34)*	6.5 (0.22)	6.4 (0.39)
ePC(36:2)	14.6 (0.50)*	9.6 (0.29)	8.6 (0.63)	15.2 (0.39)*	11.0 (0.30)	10.4 (0.52)
ePC(36:3)	4.2 (0.11)*	2.7 (0.10)	2.5 (0.15)	4.1 (0.17)*	3.0 (0.11)	3.0 (0.17)
ePC(36:4)	12.9 (0.40)*	6.5 (0.21)	5.7 (0.31)	10.8 (0.31)*	5.8 (0.64)	6.0 (0.28)
ePC(38:2)	16.5 (0.76)*	7.7 (0.27)	6.0 (0.54)	14.3 (0.50)*	7.2 (0.38)	6.4 (0.55)
ePC(38:6)	12.0 (0.31)*	5.3 (0.13)	4.5 (0.24)	8.6 (0.24)*	4.5 (0.12)	5.0 (0.24)
ePC(40:4)	7.8 (0.30)*	4.4 (0.18)	4.1 (0.27)	8.3 (0.37)*	5.4 (0.21)	4.8 (0.25)
PC(38:6)	277.3 (7.95)*	225.5 (6.47)	188.3 (11.8)	194.2 (4.35)	185.1 (5.14)	174.8 (6.28)
PC(40:4)	11.0 (0.34)*	7.5 (0.23)	6.0 (0.37)**	11.7 (0.43)	6.6 (0.24)	5.4 (0.22)
PC(40:6)	98.3 (4.38)*	75.0 (1.98)	58.7 (3.39)**	82.4 (2.13)	63.7 (2.14)	66.1 (1.68)
PC(40:7)	407.8 (2.07)*	44.5 (1.29)	36.5 (1.93)	28.9 (1.54)	32.3 (1.27)	29.4 (0.76)
eLPC(16:0)	2.8 (0.10)*	1.6 (0.04)	1.5 (0.10)	2.2 (0.07)*	1.8 (0.03)	1.8 (0.06)
eLPC(18:0)	3.3 (0.11)*	2.0 (0.06)	1.8 (0.10)	3.1 (0.06)*	2.4 (0.03)	2.3 (0.07)
LPC(16:0)	208.8 (4.30)*	155.2 (1.38)	133.8 (6.59)	158.4 (4.25)	147.7 (3.02)	142.8 (3.34)
LPC(16:1)	5.4 (0.33)	5.8 (0.23)	4.6 (0.23)	2.6 (0.20)	3.3 (0.14)	4.4 (0.11)*
LPC(18:0)	113.4 (2.72)*	77.1 (1.00)	63.7 (3.18)	103.1 (3.37)*	76.6 (2.46)	80.6 (2.25)
LPC(18:1)	57.2 (2.68)*	47.7 (1.40)	39.3 (1.73)	32.6 (1.99)	32.1 (1.09)	32.7 (0.99)
LPC(18:2)	98.9 (2.53)*	84.03 (1.57)	81.7 (3.90)	103.2 (2.94)	90.8 (3.72)	95.2 (2.28)
LPC(20:5)	7.8 (0.25)	7.6 (0.19)	6.7 (0.35)	9.0 (0.55)*	8.0 (0.32)	7.1 (0.21)
LPC(20:4)	26.0 (1.40)*	31.2 (0.55)	33.5 (1.37)	33.1 (1.32)	31.3 (0.81)	42.1 (1.22) **
LPC(22:6)	16.0 (0.62)	17.1 (0.43)	17.0 (0.75)	17.3 (0.98)	16.7 (0.47)	20.3 (0.71) **
ePE(36:5)	3.9 (0.19)*	2.3 (0.10)	2.1 (0.10)	3.0 (0.13)*	2.3 (0.09)	2.1 (0.12)
ePE(40:6)	8.0 (0.41)*	3.9 (0.11)	3.8 (0.34)	5.5 (0.26)*	3.0 (0.13)	2.8 (0.14)
PE(36:2)	16.5 (0.96)*	4.9 (0.66)	3.6 (0.47)	8.9 (0.43)*	4.9 (0.37)	3.2 (0.48)
PE(36:4)	15.7 (0.70)*	8.6 (0.23)	7.6 (0.60)	8.3 (0.34)	7.9 (0.19)	6.6 (0.38)
PE(38:5)	11.3 (0.55)	7.4 (0.22)	7.9 (0.52)	5.4 (0.37)	6.0 (0.19)	5.7 (0.34)
PE(38:6)	20.8 (0.95)*	11.5 (0.25)	10.0 (0.83)	10.3 (0.44)	10.1 (0.33)	10.0 (0.73)
PE(40:6)	4.6 (0.43)*	2.0 (0.18)	1.7 (0.18)	2.4 (0.17)	2.2 (0.17)	2.3 (0.16)
PI(36:0)	0.18 (0.01)*	0.32 (0.00)	0.02 (0.00)	0.09 (0.00)*	0.02 (0.00)	0.01 (0.00)
PI(36:1)	4.34 (0.14)*	0.8 (0.06)	0.5 (0.10)**	2.1 (0.14)*	0.52 (0.07)	0.27 (0.03)
PI(36:2)	36.4 (1.04)*	7.3 (0.61)	4.3 (0.92)**	17.8 (0.96)*	4.8 (0.67)	2.5 (0.25)
PI(36:3)	17.7 (0.61)*	6.7 (0.44)	3.6 (0.55)**	7.9 (0.37)*	3.4 (0.36)	2.2 (0.22)
PI(38:5)	15.1 (0.72)*	10.1 (0.49)	5.8 (0.59)**	7.0 (0.42)*	4.4 (0.38)	4.1 (0.36)

Note: Species which were modulated in human samples are also examined in APOE-TR and EFAD mice. * indicates p < 0.05 for higher E2 vs. E3 and E4 for APOE-TR and for higher E2FAD vs. E3 and E4FAD. ** indicates p < 0.05 for higher E4 vs. E2 and E3 for APOE-TR and for E4FAD vs. E2FAD and E3FAD. These individual species are those identified in the human cohort.